Dementia News and Research

Latest Dementia News and Research

Raptor initiates dosing in DR Cysteamine Phase 2 clinical trial for Huntington's Disease

Raptor Pharmaceutical Corp., today announced that the first patient has been dosed in its Phase 2 clinical trial of DR Cysteamine for the potential treatment of Huntington's Disease. The Phase 2 clinical trial is being conducted under a previously announced collaboration agreement with The Centre Hospitalier Universitaire d'Angers ("CHU d'Angers"), which has commenced enrolling patients at eight clinical sites throughout France.

8 Nov 2010

Eli Lilly to acquire Avid Radiopharmaceuticals

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that partner company Avid Radiopharmaceuticals, Inc. has signed a definitive merger agreement to be acquired by Eli Lilly and Company.

8 Nov 2010

Tips to reduce risk of injury in Alzheimer's patients

Caring for a loved one with Alzheimer's disease can be overwhelming. In fact, according to the Alzheimer's Association, there are more than 5 million Americans living with Alzheimer's and as many as 10 million family caregivers.

8 Nov 2010

Anti-TNF therapies may reduce Alzheimer's risk among people with rheumatoid arthritis

Anti-TNF therapies commonly used to treat rheumatoid arthritis have been found to potentially reduce the risk of developing Alzheimer's dementia among people with rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

New simple blood test may help diagnose Niemann-Pick type C disease

A fatal genetic disorder that frequently takes years to diagnose may soon be detectable with a simple blood test, researchers at Washington University School of Medicine in St. Louis and the National Institutes of Health (NIH) report this week in Simple blood test may diagnose deadly Niemann-Pick type C disease.

4 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

Study reveals a potential target for treating brain trauma

Brain damage continues to develop and evolve for months after a traumatic brain injury (TBI), revealing a potential target for treatments to improve brain trauma, new research led by the University of Melbourne, Australia has found.

3 Nov 2010

Dementia patients should receive high-quality palliative care

The system for hospice admissions for patients with advanced dementia, which is a terminal illness, should be guided by patient and family preference for comfort, not estimated life expectancy, says a new study published in the Nov. 3 Journal of the American Medical Association by the Institute for Aging Research at Hebrew SeniorLife, an affiliate of Harvard Medical School.

3 Nov 2010

New mouse model confirms mutation of beta-synuclein protein promotes neurodegeneration

A team of scientists from Japan and the University of California, San Diego School of Medicine have created a new mouse model that confirms that mutations of a protein called beta-synuclein promote neurodegeneration. The discovery creates a potential new target for developing treatments of diseases like Parkinson's and Alzheimer's.

3 Nov 2010

Drinking beet juice increases blood flow to the brain

Researchers for the first time have shown that drinking beet juice can increase blood flow to the brain in older adults - a finding that could hold great potential for combating the progression of dementia.

3 Nov 2010

Study finds DHA supplementation does not reduce risk of AD

Patients with mild to moderate Alzheimer's disease (AD) who received supplementation with the omega-3 fatty acid docosahexaenoic acid (DHA), believed to possibly reduce the risk of AD, did not experience a reduction in the rate of cognitive and functional decline, compared to patients who received placebo, according to a study in the November 3 issue of JAMA, a theme issue on aging.

3 Nov 2010

Molecular imaging technique pinpoints changes that take place in injured brain

Results from a study published in the November issue of The Journal of Nuclear Medicine (JNM) show that powerful imaging techniques positron emission tomography (PET) fused with magnetic resonance imaging (MRI) are helping researchers better understand the long-term functional and structural changes that take place after traumatic brain injury (TBI).

2 Nov 2010

Arthritis drugs also prevent post-operative cognitive decline: Study

Anti-inflammatory drugs currently used to treat diseases such as rheumatoid arthritis may also help prevent cognitive problems after surgery, according to a new study by researchers at Imperial College London and University of California, San Francisco (UCSF).

2 Nov 2010

NICE to lose its power to ban life saving drugs

Ministers have finally clarified that patients would not be denied life-extending drugs just because the NHS rationing body decides they are too expensive. National Institute for Health and Clinical Excellence (NICE) the drug watchdog in the UK will be stripped of its powers to stop drugs being available on the NHS due to price. The arbitrary limit on the cost of new drugs – around £30,000 per year of extended high-quality life – will be scrapped from 2014.

1 Nov 2010

America's biopharmaceutical companies researching 98 medicines for Alzheimer's: PhRMA report

As the champagne corks are popping this New Year's Eve, the first American Baby Boomers will turn age 65. Members of the demographic bulge that transformed American politics and culture are expected to usher in yet another momentous change a huge increase in the number of Alzheimer's disease patients.

1 Nov 2010

Mary Ann Liebert launches Brain Connectivity journal

Mary Ann Liebert, Inc. announces the release of a new peer-reviewed journal in an expanding area of systems neuroscience, Brain Connectivity. This timely new journal is positioned to become the premier source of cutting-edge basic and clinical neuroscience research aimed at better understanding of structural and functional connections in the brain and how these connections are altered by neurological disorders.

29 Oct 2010

International Congress at Spain highlights advances in neuroimmunological disease treatment

The complexity of the immune system and nervous system turn Neuroimmunology into one of the most exciting fields of modern biomedicine. Between October 26th and 30th takes place in Sitges (Barcelona, Spain) the X International Congress of Neuroimmunology of the International Society of Neuroimmunology.

29 Oct 2010

ResMed third quarter revenue increases 17% to $282.0 million

ResMed Inc. today announced record revenue and income for the quarter ended September 30, 2010. Revenue for the quarter ended September 30, 2010 was $282.0 million, a 14% increase (a 17% increase on a constant currency basis) over the quarter ended September 30, 2009.

From ResMed Corp 29 Oct 2010

Latuda tablets receive FDA approval for treatment of adults with schizophrenia

The U.S. Food and Drug Administration today approved Latuda (lurasidone HCl) tablets for the treatment of adults with schizophrenia.

29 Oct 2010

Common psychiatric drugs could slow dementia

Researchers say commonly used psychiatric drugs could be effective in slowing the progression of certain types of dementia. Dr John Kwok and colleagues from Neuroscience Research Australia have discovered a mutant gene that causes abnormal proteins build up in the brains of people with frontotemporal dementia, a disease that affects people in their 50s and 60s.

28 Oct 2010